In addition, we showed that ABL1 tyrosine kinase inhibitors, dasatinib and nilotinib, reduced HTLV-1 PVL in cultured PBMC from the HAM/TSP patients (Fig 4B). This evidence concerns the gene ABL1 and tropical spastic paraparesis.